Please note that this summary only contains information from the full scientific abstract: View ESMO Scientific Abstract

Activity of encorafenib plus binimetinib in people with melanoma that has spread to the brain

Date of summary: September 2019

The full title of this abstract is: Intracranial anti-tumour activity in melanoma brain metastases with encorafenib plus binimetinib: a multicenter, retrospective analysis

This study drug is approved to treat the condition
under study that is discussed in this summary.

 

Researchers must look at the results of many types
of studies to understand whether a study drug
works, how it works, and whether it is safe to
prescribe to patients.

This summary reports the results of only one study. The results of this study might be different from the results of other studies that the researchers look at.

 

More information can be found in the scientific
abstract of this study, which you can access here:
View ESMO Scientific Abstract

What did this study look at?

  • Melanoma is a type of skin cancer. Melanoma usually starts in the cells that give the skin its color. These cells are called melanocytes.
    • Sometimes melanoma develops in melanocytes in other parts of the body, such as the eyes and intestines.
  • Melanoma can spread from where it started to other parts of the body.
    • When this cancer spreads to the brain, it is called melanoma brain metastasis.
  • Some people with melanoma have a faulty gene called BRAF. Faulty BRAF genes make altered versions of the BRAF protein, which helps cancer cells to grow.
    • Encorafenib blocks activity of the BRAF protein.
  • Melanoma cells may have changes in other proteins too. MEK proteins go into action when BRAF proteins are altered and they help cancer cells to grow also.
    • Binimetinib blocks the activity of MEK proteins.
  • Encorafenib plus binimetinib is approved in Europe for the treatment of melanoma that:
    • has a faulty BRAF gene and cannot be removed by surgery, or
    • has spread to other parts of the body.
  • This study looked at encorafenib plus binimetinib in people with altered proteins and melanoma that had spread to the brain.
    • This study is a case series, not a clinical trial. This means the researchers looked back at people with melanoma brain metastasis who received the same treatment as part of standard clinical care.
  • This summary describes how people’s melanoma responded to encorafenib plus binimetinib:
    • inside the brain
    • outside of the brain, and
    • overall in the body.

Who took part in this study?

  • At the start of the study:
    • Everyone had received 2 previous treatments, on average, over about 17 months since their melanoma diagnosis.
    • Everyone had been diagnosed with melanoma brain metastasis around 2 months previously.
    • Fourteen people had already taken other treatments previously that block altered BRAF and MEK proteins.

What were the results of the study?

*People may not have been able to be assessed for many reasons, such as:
– an image of their cancer was not done, or redone, at a set time point in the study.
– the scan of their cancer was done differently than it was before.
– a medical problem could have occurred.

  • Overall, for people in this study:
    • The results for cancers inside the brain were similar to cancers outside of the brain and in the body overall.
    • Encorafenib plus binimetinib did not cause any medical problems that have not already been seen in people in
      other studies whose melanoma had not spread to the brain.

More results from this study can be found here:
View ESMO Scientific Abstract

What were the main conclusions reported by the researchers?

  • In this study, some people with melanoma brain metastasis had cancer that shrank or completely
    disappeared (meaning it responded) after treatment with encorafenib plus binimetinib.

    • Some people responded to treatment, even after other previous BRAF and MEK treatments stopped
      working.
  • Researchers want to do a similar clinical study in the future. Next time they want to follow people
    forward over time rather than look back at what happened.

Who sponsored this study?

Pfizer Inc.
235 East 42nd Street NY, NY 10017
Phone (United States): +1 212-733-2323

Pfizer would like to thank all of the
people who took part in this study.

Array BioPharma Inc (a subsidiary of Pfizer Inc)
3200 Walnut Street
Boulder, CO 80301
Phone (United States): +1 303-381-6600

Click to show further information on the study and clinical trials in general